More than 50% of all cancer patients will at some point during their treatment receive external radiation therapy. However, traditional radiation therapy also irradiates healthy tissue, leading to serious side effects. Curasight's new type of radiation therapy solves this issue, as the company’s technology builds on the principle called Targeted Radionuclide Therapy.
With Curasight's technology, the patient is not irradiated from the outside, but instead a substance is injected into a blood vessel and automatically seeks out and only binds to the cancer cells. From there, the substance sends out radiation with a range of just one millimetre, irradiating the cancer while minimizing irradiation of healthy tissue.
By using imaging, it is possible to know for sure that the therapy reaches the cancer. The exact same substance that is used for therapy, just modified for imaging, can exactly predict where the therapy will work. This is called the Theranostic (Therapy – Diagnostics) principle. By starting with imaging, only patients with a clear tumour uptake will proceed to targeted radionuclide therapy. This is personalised, tailored cancer therapy.
Curasights technology to find, visualise and predict whether a cancer is aggressive and if so, how it should be treated.
Curasights new type of personalised and tailored targeted radiation therapy.
Curasight's novel and innovative Theranostics platform for improved cancer diagnose and treatment.
Nuclear medicine in brief
Nuclear medicine involves the application of radioactive substances in the diagnosis and treatment of disease. This is done by recording radiation emitting from within the body. This differs from external radiation, where images are generated by external sources of energy such as X-rays. Often nuclear medicines can treat parts of the body where traditional external radiation is not useful as vital organs and healthy tissue around the cancer is also radiated. That is the limitation of traditional external radiation.